Previous 10 | Next 10 |
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration with MapKure, LLC, a clinical-stage company focusing on genetically defined disease drivers and jointly owned by BeiGene, Ltd. and SpringWorks Therapeutics, Inc., to use a clinical...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has appointed Dr. Woodrow (Woody) Myers to its Board of Directors and to the Nominating and Corporate Governance Committee of the Board. The company also announce...
Personalis, Inc. (PSNL) Q4 2020 Earnings Conference Call February 25, 2021 17:00 ET Company Participants Caroline Corner - Investor Relations John West - President and Chief Executive Officer Aaron Tachibana - Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of Ameri...
Personalis (PSNL): Q4 GAAP EPS of -$0.34 misses by $0.04.Revenue of $20.18M (+11.2% Y/Y) beats by $0.16M.2021 Guidance: Revenues to be ~$20.3M; revenues from biopharma and all other customers, excluding VA MVP, to be in the range of $5.6-$7M and net loss of $14-$15M.Shares -6.88%.Press R...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter Highlights Record quarterly revenue of $20.2 million in the fo...
Second paragraph, first sentence of release dated February 11, 2021, should read: Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 5065084. (instead of Interested pa...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced that the two companies have entered into a partnership in the field of personalized oncology. The partnership will pair P...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market closes on Thursday, February 25, 2021. In conjunction with the release, the Company will host a conference call and webca...
Personalis (PSNL) appoints of Susan Moriconi as VP of People and Chief Human Resources Officer.Earlier in her career, Ms. Moriconi served as VP of HR at several established healthcare and technology companies – including Boston Scientific, Stanford Healthcare, ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the appointment of Susan Moriconi as VP of People and Chief Human Resources Officer. Ms. Moriconi joins Personalis from Omnicell, Inc. (Nasdaq: OMCL), where she most ...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tum...